NCT05528055View on ClinicalTrials.gov

A Study to Investigate the Safety and Tolerability of SCR-6920 Capsule in Patients With Advanced Malignant Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

122

Participants

Timeline

Start Date

May 18, 2022

Primary Completion Date

October 31, 2027

Study Completion Date

October 31, 2027

Conditions
Solid TumorNon Hodgkin Lymphoma
Interventions
DRUG

SCR-6920 capsule

SCR-6920 capsule will be oral administered once daily at escalating doses on a continuous basis

DRUG

SCR-6920 capsule

SCR-6920 capsule will be oral administered once daily at the recommended phase 2 dose on a continuous basis

DRUG

SCR-6920 capsule

SCR-6920 capsule will be oral administered once daily at the recommended phase 2 dose on a continuous basis

DRUG

SCR-6920 capsule

SCR-6920 capsule will be oral administered once daily at the recommended phase 2 dose on a continuous basis

Trial Locations (1)

250117

RECRUITING

Shandong Cancer Hospital, Jinan

Sponsors
All Listed Sponsors
lead

Jiangsu Simcere Pharmaceutical Co., Ltd.

INDUSTRY

NCT05528055 - A Study to Investigate the Safety and Tolerability of SCR-6920 Capsule in Patients With Advanced Malignant Tumors | Biotech Hunter | Biotech Hunter